Physician profile

John Sharp

Nurse Practitioner · Danville, PA

NPI 1346764347

$677.77

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$202.02

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $162.01 2021-2022
Tandem Diabetes Care, INC. $153.76 2023-2024 T:Slim X2 Insulin Pump With Control-Iq
Astrazeneca Pharmaceuticals Lp $114.30 2021
Bayer Healthcare Pharmaceuticals INC. $68.33 2021-2022
Abbott Laboratories $52.25 2021-2022
Dexcom, INC. $48.26 2023 Dexcom G6 Transmitter
Medtronic, INC. $39.55 2021-2022
Abbvie INC. $25.72 2021-2022
Novo Nordisk INC $13.59 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Sharp

$677.77

in general payments reported 2019-2025

Years
2021-2024
Top company
Lilly USA, LLC

https://glasscript.com/doctor/10891212/john-sharp

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.